Aktienanalyse zu Exagen Inc (XGN)XGNExagen Inc

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Exagen Inc is a good buy right now, trading at $7.39 with a recent RSI of 54.76 indicating neutral momentum. The company reported a record revenue of $19.9 million in Q2 2026, which is a 16% year-over-year increase, and has raised its full-year revenue guidance to $72 million to $75 million. This growth trajectory, combined with a gross margin improvement to over 61%, suggests strong operational efficiency and market demand. However, the main risk is the negative net income, which was -$3.2 million in Q2 2026, indicating ongoing financial challenges that investors should consider.